Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
    • Transcripts
    • AGM Invitations
    • IPOs
  • inderesTV
  • Portfolio
  • Forum
  • Discovery
  • Premium
  • Femme
  • Nora AI
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Log in to your Inderes Free account to see all free content on this page.
Create account

Optomed

2.41 EUR

+1.05 %

5,656 following
Corporate customer

OPTOMED

NASDAQ Helsinki

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+1.05 %
-9.91 %
-36.07 %
-36.07 %
-34.78 %
-37.65 %
-38.68 %
-60.36 %
-47.38 %

Optomed operates in the medical technology sector. The company conducts research and development of specialized eye cameras. Development takes place of both hardware and software that are resold under different brands. Operations are held on a global level, with the largest presence in the Nordic market. Customers consist of research institutes and hospitals. The company has its headquarters in Oulu.

Read more
Market cap
51.7M EUR
Turnover
96.2K EUR
P/E (adj.) (26e)
EV/EBIT (adj.) (26e)
P/B (26e)
EV/S (26e)
Dividend yield-% (26e)
Coverage
Recommendation
Buy
Target price
Updated
11.02.2026
Disclaimer
Juha Kinnunen
Juha Kinnunen

Analyst

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
6.5.
2026

Interim report Q1'26

8.5.
2026

General meeting '26

14.8.
2026

Interim report Q2'26

Risk
Business risk
Valuation risk
Low
High
All
Research
Webcasts
Press releases
ShowingAll content types
US market roadmap for medical devices – a European perspective
Analyst Comment3/27/2026, 10:45 AM by
Antti Siltanen

US market roadmap for medical devices – a European perspective

Success in the US requires success in several sub-areas.

BioretecAiforia TechnologiesNightingale HealthNexstimOptomedRevenio GroupModulightBiohit
Regulatory press release2/27/2026, 7:00 AM

Optomed Oyj: Disclosure under Chapter 9, Section 10 of the Securities Markets Act regarding change in holdings

Optomed
Regulatory press release2/25/2026, 7:00 AM

Optomed Oyj: Optomed Annual Report 2025 published

Optomed

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Press release2/11/2026, 12:31 PM

Redeye: Optomed Q4 (Review): Devices segment supports outlook despite cautious guidance

Optomed
Press release2/10/2026, 12:16 PM

Redeye: Optomed Q4 (Initial take): Sales in line; EBIT impacted by a one-off cost

Optomed
Regulatory press release2/10/2026, 7:00 AM

Optomed Oyj: Optomed Plc: Financial Statements Bulletin January - December 2025

Optomed
Regulatory press release1/29/2026, 11:30 AM

Optomed Oyj: Proposal of Optomed's Nomination Board

Optomed
Press release1/21/2026, 9:00 AM

Optomed Oyj: Optomed Achieves ISO 27001 Certification for Information Security Management Systems

Optomed
Press release1/12/2026, 7:00 AM

Optomed Oyj: Optomed and Aireen Announce Strategic Partnership and Achieve Approval for AI-Powered Handheld Diabetic Retinopathy Screening

Optomed
Life Science Companies as Investments | Life Science Night Dec. 9, 202514:40
Video12/16/2025, 7:30 AM

Life Science Companies as Investments | Life Science Night Dec. 9, 2025

Antti Siltanen, Life Science Analyst, PhD, talks about life science companies as investments.

Aiforia TechnologiesBioretecBiohitFaron PharmaceuticalsModulightNexstimOrionBittiumDetection TechnologyOptomedRevenio GroupNightingale HealthHerantis PharmaNanoform Finland
Regulatory press release12/12/2025, 1:45 PM

Optomed Oyj: New shares subscribed for in Optomed Plc's directed share issue have been registered in the Finnish Trade Register

Optomed
Regulatory press release12/10/2025, 8:00 PM

Optomed Oyj: Inside information: Optomed Plc successfully completes directed share issue raising approximately EUR 6.0 million

Optomed
Press release11/7/2025, 7:48 AM

Redeye: Optomed Q3 (Review) - Solid growth with a positive devices segment development

Optomed
Regulatory press release11/6/2025, 7:00 AM

Optomed Oyj: Optomed Plc: Interim Report, January - September 2025

Optomed
Regulatory press release9/26/2025, 1:30 PM

Optomed Oyj: Optomed Plc - Managers' transactions - Myllylä

Optomed
Regulatory press release9/26/2025, 1:30 PM

Optomed Oyj: Optomed Plc - Managers' transactions - Piila

Optomed
Regulatory press release9/26/2025, 1:30 PM

Optomed Oyj: Optomed Plc - Managers' transactions - Himberg

Optomed
Regulatory press release9/26/2025, 1:30 PM

Optomed Oyj: Optomed Plc - Managers' transactions - Knuutti

Optomed
Regulatory press release9/23/2025, 6:00 AM

Optomed Oyj: Optomed's Board has resolved upon a new option plan

Optomed
Regulation of medical devices and diagnostics in Europe
Analyst Comment9/19/2025, 5:18 AM by
Antti Siltanen

Regulation of medical devices and diagnostics in Europe

The EU is the world's second largest market for medical devices after the United States. In this article, we will go through the basics of EU regulation from an investor's perspective.

BioretecAiforia TechnologiesNexstimBiohitOptomedRevenio GroupModulightDetection TechnologyNightingale HealthBittium
Forum discussions
Aurora is in use in India. karthikhospital.in Best Diabetologist in wilson garden, Bangalore | Diabetologist In Wilson ... Best Diabetologist It doesn’t seem to provide a direct link to the page even if you include it. From the menu, select ……services …..eye fundus examination …....
15 hours ago
by j.sälli
14
This has received relatively little speculation. Perhaps for good reason, referring to previous observations and the revenue that has surfaced so far. But when one investigates this a little, it cannot be a coincidence that Aria Care Partners chooses AEYE Health’s marketing image...
13 hours ago
by Due Diligence
12
I would rather say that the Aurora AEYE story is overshadowed by the declining and weak consulting business.
16 hours ago
by GTonic
5
“The patient sits in front of the tabletop device and places their chin in the chin rest.” In my opinion, that quote practically confirms that it’s not Optomed’s solution being used, but rather a tabletop camera.
23 hours ago
by Due Diligence
5
At least I don’t have any greater wisdom on this. And my expertise isn’t enough to assess it. Quite a sensible thought.
12 hours ago
by Due Diligence
2
I wonder if that’s just a paid ad What do you think?
13 hours ago
by Tobias
2
I’m guessing that one contributing factor to this share price decline is that some investors believe the weak performance of the software segment indicates that the AI product isn’t gaining traction. They don’t know that the Aurora AEYE service is reported under the hardware segment...
16 hours ago
by Tobias
1
Read more on our forum
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.